Vagal Nerve Stimulation in mTBI
Recruiting
Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) are important conditions for the Veterans Administration (VA) that frequently occur together in combat Veterans from the conflicts in Afghanistan and Iraq. In many Veterans these become chronic, raising the risk the burden of neurotrauma can worsen over time. This study will examine a new intervention called non-invasive Vagal Nerve Stimulation (nVNS) and its effects on memory and symptoms of PTSD and mTBI as well as bra... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/19/2025
Locations: Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia
Conditions: PTSD, mTBI
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
Recruiting
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem cells (MSC). The purpose of the phase II trial is to compare the effect of MSC with standard of care in these patients. MSCs are a type of stem cells that can be taken from umbilical cord blood and grown into many different cell types t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in Pt. W/ Metastatic PAC
Recruiting
This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
4D-MRI for Precision Medicine
Recruiting
The purpose of this study is to develop new ways to make medical images of the lungs and liver of adults using a technique called four-dimensional magnetic resonance imaging (4D-MRI). This technique produces three-dimensional movies of the inside of the chest and abdomen while the patient is breathing. (The fourth dimension is time!) This new way of medical imaging is being developed to help cancer patients undergoing radiation therapy. Radiation therapy is used to treat cancerous tumors. For r... Read More
Gender:
ALL
Ages:
Between 18 years and 82 years
Trial Updated:
03/19/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Healthy Volunteers, Liver Cancer, Lung Cancer
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Recruiting
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical tria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Stanford University, Stanford, California
Conditions: Triple Negative Breast Cancer, Breast Cancer
Mosunetuzumab with Lenalidomide Augmentation As First-line Therapy for Follicular and Marginal Zone Lymphoma
Recruiting
BrUOG-401 is a prospective, single-arm, phase 2 trial of first-line therapy in adult patients with previously untreated FL or MZL. All patients will be assigned the same initial treatment plan, modified by interim response assessment (IRA) after Cycle 4. All patients will start treatment with four 21-day cycles (C1-4) of mosunetuzumab alone (using step-up dosing during C1), followed by IRA. Patients who achieve CR at IRA will continue with additional 4 cycles (C5-8) of mosunetuzumab. Patients wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Yale Cancer Center, New Haven, Connecticut +2 locations
Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
Understanding Allergies and Sensitizations in Healthy and Allergic Individuals
Recruiting
The purpose of this study is to strengthen our ability to accurately diagnose allergies and understand cellular, humoral, genetic components and physiological changes in allergic disease
Gender:
ALL
Ages:
Between 1 week and 90 years
Trial Updated:
03/19/2025
Locations: Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Palo Alto, California
Conditions: Allergy
Pilot RCT of Self-stigma Treatment for First Episode Psychosis
Recruiting
The overall purpose of the proposed exploratory intervention development application, is to conduct research that will inform the adaptation and preliminary testing of NECT modified for youth (aged 15-24) with first episode psychosis (FEP), targeting self-concept and illness conceptions to increase treatment engagement. The specific aims of the project are to: 1) adapt NECT to be responsive to the needs and preferences of youth with FEP, and 2) Assess the feasibility, acceptability and prelimina... Read More
Gender:
ALL
Ages:
Between 15 years and 24 years
Trial Updated:
03/19/2025
Locations: Eskenazi Health, PARC Program, Indianapolis, Indiana
Conditions: First Episode Psychosis, Youth
BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
Recruiting
This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy (SBRT) delivered concurrently. Only patients who proceed to surgery will be evaluable for the primary endpoint. The primary efficacy outcome measurement will be pathologic response (including Major Pathologic Response (MPR), and Complete Pathologic Response (CPR)). Secon... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Rhode Island Hospital, Providence, Rhode Island
Conditions: Non Small Cell Lung Cancer
SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care
Recruiting
In a prior application (MH064372), the investigators' treatment research program (Services for Kids In Primary-care, SKIP) developed and tested a chronic care model-based intervention, called Doctor Office Collaborative Care (DOCC), that was found to be effective in the management of childhood behavior problems and comorbid ADHD. In the "SKIP for PA Study", the investigators propose to conduct a randomized clinical trial to evaluate the effects of team- and practice leadership-level implementati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Drexel University, Philadelphia, Pennsylvania +1 locations
Conditions: Child Behavior Problem, Attention Deficit and Disruptive Behavior Disorders
Tumor Treating Fields for the Treatment of Brainstem Gliomas
Recruiting
This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with cancer cell division. TTFields may prevent growth or decrease size of gliomas in patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Emory Proton Therapy Center, Atlanta, Georgia +2 locations
Conditions: Glioma
Physio-Anatomy Clinical Data Collection Study
Recruiting
This is an on-label clinical study design intended for the collection of three different types of interventional procedural data using FDA-cleared cardiac catheterization technologies and drugs, each used according to its product labeling and standard practice of medicine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Veteran's Administration Palo Alto, Palo Alto, California +5 locations
Conditions: Coronary Stenosis